Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses.

Abstract

INTRODUCTION:

Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination therapy in non-responders to PDE5i. We will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.

METHODS AND ANALYSIS:

This overview was designed in accordance with the PRIO-harms and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and its protocol was registered at PROSPERO. We will systematically search PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. We will include systematic reviews or meta-analyses: (1) comparing the efficacy and safety of any dose of PDE5i with each other, with placebo or with other effective treatments for the management of erectile function; (2) exploring the use of any PDE5i alone or in combination with other treatment modalities in the general male population or in specific subgroups and (3) conducted with systematic procedures. Our overview will employ the AMSTAR 2 tool to evaluate the quality of the included studies and the Grading of Recommendations Assessment, Development and Evaluation approach to assess the strength of evidence for all outcomes. We will construct forest plots of risk estimates with the corresponding CI for all outcomes.

ETHICS AND DISSEMINATION:

In this overview, we will undertake an extensive literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i versus another or versus placebo and provide recommendations for clinicians and policy-makers. No ethical approval is required.

PROSPERO REGISTRATION NUMBER:

CRD42020216754.

• Authors: Nikolaos Pyrgidis, Ioannis Mykoniatis, Anna-Bettina Haidich, Maria Tirta, Persefoni Talimtzi, Dimitrios Kalyvianakis, Andreas Ouranidis, Dimitrios Hatzichristou
• Journal: BMJ open (BMJ Open) Vol. 11 Issue 8 Pg. e047396 (08 24 2021) ISSN: 2044-6055 [Electronic] England
• PMID: 34429310 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Phosphodiesterase 5 Inhibitors
• Phosphoric Diester Hydrolases

Topics

• Erectile Dysfunction (drug therapy)
• Humans
• Male
• Phosphodiesterase 5 Inhibitors (adverse effects)
• Phosphoric Diester Hydrolases
• Systematic Reviews as Topic
• Treatment Outcome